Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 20 April 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Recombinant human activated protein C reduces mortality from severe sepsis

Recombinant human activated protein C significantly reduces mortality in patients with severe sepsis, according to research conducted by an international team.

News image

fiogf49gjkf04

The team conducted a Phase III trial, in which they assessed whether treatment with drotrecogin alfa (recombinant human activated protein C) reduced the rate of death from any cause among patients with severe sepsis.

They reported their findings in this week's New England Journal of Medicine.

Patients with systemic inflammation and organ failure due to acute infection were enrolled in the randomized, double-blind trial. Each was assigned to receive an intravenous infusion of either placebo or drotrecogin alfa activated for a total duration of 96 hours.

The prospectively defined primary end-point was death from any cause, and was assessed 28 days after the start of the infusion.

Patients were monitored for adverse events; changes in vital signs, laboratory variables, and the results of microbiologic cultures; and the development of neutralizing antibodies against activated protein C.

A total of 1,690 patients were treated (840 in the placebo group and 850 in the drotrecogin alfa activated group).

The mortality rate was found to be 30.8% in the placebo group and 24.7% in the drotrecogin alfa activated group.

Effect of activated drotrecogin alfa treatment:
- Reduction in relative risk of death of 19.4%
- Absolute reduction in risk of death of 6.1%
New England Journal of Medicine

On the basis of the prospectively defined primary analysis, treatment with drotrecogin alfa activated was associated with a reduction in the relative risk of death of 19.4% and an absolute reduction in the risk of death of 6.1%.

The incidence of serious bleeding was higher in the drotrecogin alfa activated group than in the placebo group (3.5% vs. 2.0%).

Gordon Bernard, of the Vanderbilt University School of Medicine, Nashville, USA, concluded on behalf of the team, "Treatment with drotrecogin alfa activated significantly reduces mortality in patients with severe sepsis but may be associated with an increased risk of bleeding."

In an accompanying editorial, Michael A. Matthay, of the University of California, San Francisco, comments, "Activated protein C should be given to patients who meet all the inclusion criteria, including evidence of end-organ dysfunction with shock, acidosis, oliguria, or hypoxemia.

"The risks and benefits of the agent must be studied in patients at a higher risk of bleeding, in children, and in immunosuppressed patients, especially those with thrombocytopenia or neutropenia."

"The investigators have provided evidence that mortality can be reduced among patients with severe sepsis through the use of a new therapy that inhibits both the procoagulant and the inflammatory cascades," he concludes.

N Engl J Med 2001; 344: 699-709
14 March 2001

Go to top of page Email this page Email this page to a colleague

 20 April 2018 
Antibody suitable for further clinical development to complement existing therapeutic strategies for HCV
 20 April 2018 
Obesity and physical activity in diverticulosis
 20 April 2018 
Worldwide H.pylori prevalence
 20 April 2018 
Adalimumab with azathioprine in Crohn's
 19 April 2018 
Fibrosis in patients with chronic hepatitis B
 19 April 2018 
c-Myc expression and pancreatic cancer
 19 April 2018 
Olmesartan prescription in the USA
 18 April 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 18 April 2018 
Hep C treatment for sustained virologic response
 18 April 2018 
Endoscopic necrosectomy reduces risk of death 
 17 April 2018 
Colorectal cancer screening and ethnic inequities
 17 April 2018 
Training programs should consider radiation education for advanced endoscopy fellows
 17 April 2018 
Aspirin and pancreatic cancer
 16 April 2018 
Surgery for colorectal polyps has increased 
 16 April 2018 
Advanced fibrosis can be ruled out in primary health care patients
 16 April 2018 
Antibiotic use and colorectal adenoma
 13 April 2018 
Colorectal cancer cell lines
 13 April 2018 
Infliximab and corticosteroid-free clinical remission in Crohn's
 13 April 2018 
Teduglutide for children with short bowel syndrome
 12 April 2018 
Prescriptions for opiate drugs amongst primary care patients with IBD
 12 April 2018 
Lower GI bleeding related to comorbidity
 12 April 2018 
non–Clostridium difficile bacterial infections in IBD
 11 April 2018 
Physician perception of IBD trial results
 11 April 2018 
Bile acid deficiency in IBS 
 11 April 2018 
Stem cell therapy for fistulas in Crohn's
 10 April 2018 
Overweight in childhood and type 2 diabetes
 10 April 2018 
immunoglobulin G associates with clinical features of IBD
 10 April 2018 
T-cells repertoires in celiac disease
 09 April 2018 
Biomarker tests for colorectal cancer screening
 09 April 2018 
Fecal transplantation in C. difficile infection and treatment outcome 
 09 April 2018 
No weigh-loss drug improved all cardiometabolic risk factors
 06 April 2018 
Colonoscopy and colorectal cancer mortality
 06 April 2018 
Eosinophilic esophagitis and health-related quality of life
 06 April 2018 
Microbiome in athletes vs sedentary subjects
 05 April 2018 
Laparoscopic Nissen fundoplication for GERD treatment
 05 April 2018 
Random biopsies for neoplasia in IBD
 05 April 2018 
Scoring system identifies cancer risk in Barrett's
 04 April 2018 
Alpha‐1 antitrypsin deficiency and liver disease
 04 April 2018 
PPI and risk of stroke
 04 April 2018 
Adjuvant chemotherapy for advanced colon cancer
 29 March 2018 
Prevention of metachronous gastric cancer
 29 March 2018 
Acute lower GI bleeding
 28 March 2018 
Decision aid used by IBD patients
 28 March 2018 
Transition for young adults with IBD
 28 March 2018 
Amitriptyline in functional dyspepsia
 27 March 2018 
Emergency department utilization for IBD 
 27 March 2018 
Management of hemorrhoids in the USA
 27 March 2018 
Adult ulcerative colitis
 26 March 2018 
Biological therapy response in IBD 
 26 March 2018 
Obesity and diverticulosis
 26 March 2018 
Practice guidelines for chronic constipation
 23 March 2018 
Health-related quality of life in eosinophilic esophagitis
 23 March 2018 
Genetics and chronic liver disease
 23 March 2018 
Global prevalence of H.pylori
 22 March 2018 
H. pyloris and gastric cancer
 22 March 2018 
Pancreatitis after IBS treatment 
 22 March 2018 
Mechanisms of action in patients with IBS
 21 March 2018 
Panel markers for early detection of colon cancer

 21 March 2018 
Blood test differentiates celiac disease
 21 March 2018 
Patient characteristics and colonoscopy preparation

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us